

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 553862244 US, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22315-1450, on the date shown below.

Dated: May 13, 2005

Signature:


(Megan E. Williams)

Docket No. HUI-021CNRCE3
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Laurie H. Glimcher *et al.*

Application No. 09/248,756

Confirmation No. 9168

Filed: February 12, 1999

Art Unit: 1636

For: METHODS AND COMPOSITIONS FOR
REGULATING T CELL SUBSETS BY
MODULATING TRANSCRIPTION FACTOR
ACTIVITY

Examiner: G. G. Leffers

INFORMATION DISCLOSURE STATEMENT

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants withdraw the parent case from issue in order to seek entry of this Information Disclosure Statement. This Information Disclosure Statement is being filed concurrently with a Request for Continued Examination.

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form SB-08, and in accordance with 37 CFR §1.97 a copy of each cited publication was filed in the parent case USSN 08/636,602. Copies of the references on the PTO/SB/08 are not provided.


This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se*

as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR § 1.97(b)(4), no additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

Dated: May 13, 2005

Respectfully submitted,

By 
Megan E. Williams
Registration No. 43,270
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney For Applicants



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/248,756-Conf.#9168
				Filing Date	February 12, 1999
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1636
				Examiner Name	G. G. Leffers
Sheet	1	of	3	Attorney Docket Number	HUI-021CNRCE3


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A1	WO 95/27500	10/95	PCT		
	A2	WO 95/24425	09/95	PCT		
	A3	EP 585 681 A2	03/94	EPO		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A4	Andrews, N.C. et al., "The ubiquitous subunit of erythroid transcription factor NF-E2 is a small basic-leucine Zipper protein related to the v-maf oncogene", <i>Proc. Natl. Acad. Sci. USA</i> , vol. 90, pp. 11488-11492 (1993);	
	A5	Casolaro, V., et al., "Inhibition of NF-AT-dependent transcription by NF-kappa B: implications for differential gene expression in T helper cell subsets", <i>Proc Natl Acad Sci USA</i> , vol. 92, pp. 11623-11627 (1995);	
	A6	Cordes, S.P. et al., "The mouse segmentation gene <i>kr</i> encodes a novel basic domain-leucine zipper transcription factor", <i>Cell</i> , pp. 1025-1034 (1994);	
	A7	Engel, J.D., "Meticulous AP-1 factors", <i>Nature</i> , vol. 367, pp. 516-517 (1994);	
	A8	Hodge, M.R. et al., "The proximal promoter of the IL-4 gene is composed of multiple essential regulatory sites that bind at least two distinct factors", <i>Journal of Immunology</i> vol. 154, No. 12, pp. 6397-6405 (1995);	
	A9	Hodge, M.R. et al., "Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient mice", <i>Immunity</i> vol. 4, pp. 397-405 (1996);	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/248,756-Conf.#9168
				Filing Date	February 12, 1999
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1636
				Examiner Name	G. G. Leffers
Sheet	2	of	3	Attorney Docket Number	HUI-021CNRCE3

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	B1	Fujiwara, K.T. et al., "Two new members of the maf oncogene family, mafK and mafF, encode nuclear b-Zip proteins lacking putative trans-activator domain", <i>Oncogene</i> , vol. 8, pp. 2371-2380 (1993);		
	B2	Igarashi, K. et al., "Conditional expression of the ubiquitous transcription factor MafK induces erythroleukemia cell differentiation", <i>Proc. Natl. Acad. Sci. USA</i> , vol. 92, pp. 7445-7449 (1995);		
	B3	Igarashi, K. et al., "Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins", <i>Nature</i> , vol. 367, pp. 568-572 (1994);		
	B4	Igarashi, K. et al., "Activity and expression of murine small Maf family protein MafK", <i>J. Biol. Chem.</i> , vol. 270, pp. 7615-7624 (1995);		
	B5	Itoh, K. et al., "Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins", <i>Mol. Cell. Biol.</i> , vol. 15:8, pp. 4184-4193 (1995);		
	B6	Kataoka, K. et al., "Transactivation activity of Maf nuclear oncoprotein is modulated by Jun, Fos and small Maf proteins", <i>Oncogene</i> , vol. 12, pp. 53-62 (1996);		
	B7	Kataoka, K. et al., "Small Maf proteins heterodimerize with Fos and may act as competitive repressors of the NF-E2 transcription factor", <i>Mol. Cell. Biol.</i> , vol. 15:4, pp. 2180-2190 (1995);		
	B8	Kataoka, K. et al., "Maf nuclear oncoprotein recognizes sequences related to an AP-1 site and forms heterodimers with both Fos and Jun", <i>Mol. Cell. Biol.</i> , vol. 14:1, pp. 700-712 (1994);		
	B9	Kataoka, K. et al., "Structure-Function Analysis of the maf Oncogen Product, a Member of the b-Zip Protein Family", <i>J. Virol.</i> , vol. 67:4, pp. 2133-2141, (1993);		
	B10	Kawai, S. et al., "Isolation of the avian transforming retrovirus, AS42, carrying the v-maf oncogene and initial characterization of its gene product", <i>Virology</i> , vol. 88, pp. 778-784 (1992);		
	B11	Kerppola, T.K. et al., "Maf and Nrl can bind to AP-1 sites and form heterodimers with Fos and Jun", <i>Oncogene</i> , vol. 9, pp. 675-684 (1994);		
	B12	Kurschner, C. et al., "The maf proto-oncogene stimulates transcription from multiple sites in a promoter that directs purkinje neuron-specific gene expression", <i>Mol. Cell. Biol.</i> , vol. 15:1, pp. 246-254 (1995);		
	B13	Liu, Q. et al., "Expression of the bZIP transcription factor gene Nrl in the developing nervous system", <i>Oncogene</i> , vol. 12, pp. 207-211 (1996);		
	B14	Nishizawa, M. et al., "v-maf, a viral oncogene that encodes a "leucine zipper" motif", <i>Proc. Natl. Acad. Sci. USA</i> , vol. 86, pp. 7711-7715 (1989);		
	B15	Rooney, J.W. et al., "A common factor regulates both Th1- and Th2 -specific cytokine gene expression", <i>EMBO Journal</i> , vol. 13(3), pp. 625-633 (1994);		
	B16	Rooney, J.W. et al., "Coordinate and cooperative roles for NF -AT and AP-1 in the regulation of the murine IL - 4 gene", <i>Immunity</i> , vol. 2, pp. 473-483 (1995);		
Examiner Signature				Date Considered



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/248,756-Conf.#9168
				Filing Date	February 12, 1999
				First Named Inventor	Laurie H. GLIMCHER
				Art Unit	1636
				Examiner Name	G. G. Leffers
				Attorney Docket Number	HUI-021CNRCE3
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	Sieweke, M.H. et al., "MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation", <i>Cell</i> , vol. 85, pp. 49-60 (1996);		
	C2	Swaroop, A. et al. "A conserved retina-specific gene encodes a basic motif/leucine zipper domain", <i>Proc. Natl. Acad. Sci. USA</i> , vol. 89, pp. 266-270 (1992);		
	C3	Tara, D. et al., "Characterization of the constitutive and inducible components of a T cell IL - 4 activation responsive element", <i>J Immunol</i> , vol. 154(9), pp. 4592-602 (1995);		
	C4	Wierenga, E.A. et al., "Reduced NF -AT binding at the IL - 4 -CLEO. element in TH2 cells of atopic patients; <i>9th International Congress of Immunology</i> , Abstract 4155, July 23-29 1995;		
	C5	Yang-Feng, T.L. et al., "Neural retina-specific leucine zipper gene NRL (D14S46E) maps to human chromosome 14q11.1-q11.2", <i>Genomics</i> , vol. 14, pp. 491-492 (1992).		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--